Form 4: Cardiff Oncology Director James Armitage Granted 40,565 Stock Options

James O. Armitage, a Director at Cardiff Oncology, Inc., was granted 40,565 stock options with an exercise price of $3.16, as disclosed in a recent SEC Form 4 filing.

Summary

• Director James O. Armitage of Cardiff Oncology, Inc. was granted 40,565 stock options on June 26, 2025.
• The exercise price for these newly granted options is $3.16 per share.
• These options will become exercisable on June 26, 2026, and have an expiration date of June 26, 2035.
• Following this transaction, Mr. Armitage beneficially owns a total of 187,539 derivative securities, specifically stock options, directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine disclosure of an insider stock option grant, which is a standard component of executive and director compensation and does not inherently indicate positive or negative company performance.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.

Future Outlook

The document, an SEC Form 4, is a disclosure of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine disclosure of an insider equity transaction, common across all publicly traded companies, and does not provide specific insights into broader industry trends or competitive landscape beyond the company's internal compensation practices.

Related Party Transactions

• Grant of stock options to Director James O. Armitage, which is a transaction between the company and a related party (director) as part of his compensation.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also increased alignment of the director's interests with long-term shareholder value creation.

Next Steps

• The granted stock options will become exercisable on June 26, 2026.

Key Dates

Keywords

SEC Form 4, Cardiff Oncology, CRDF, Stock Options, Insider Transaction, Beneficial Ownership, Director Compensation, Equity Grant